Aspirin slows spread of colon, pancreatic cancer in tumor cells

Researchers have found that aspirin may slow the spread of some types of colon and pancreatic cancer cells according to Science daily.

Platelets are blood cells involved with clotting. They promote the growth of cancerous cells by releasing growth factors and increasing the response of certain proteins that regulate tumor cell development (oncoproteins). Low doses of aspirin, an anti-platelet drug, have been shown to reduce the risk of some types of gastrointestinal cancers, but the process by which aspirin hampers tumor growth has been unclear. “The current study was designed to determine the effect of inhibition of platelet activation and function by aspirin therapy on colon and pancreatic cancer cell proliferation,” the researchers wrote.

 

The research team combined activated platelets primed for the clotting process with three groups of cancer cells: • metastatic colon cancer (cells that have spread outside the colon), • nonmetastatic colon cancer (cells that grow only within the colon) and • nonmetastatic pancreatic cancer cells.

When they added aspirin to the mixture, they found that the platelets were no longer able to stimulate growth and replication in the pancreatic and nonmetastatic colon cancer cells. The metastatic colon cancer cells continued to multiply when treated with aspirin.

In pancreatic cancer cells, low doses of aspirin stopped the platelets from releasing growth factor and hampered the signaling of the oncoproteins that cause cancer to survive and spread. Only very high doses — larger than are possible to take orally — were effective in stopping growth in the metastatic colon cells, explained the researchers.

The findings detail the interaction among platelets, aspirin and tumor cells and are promising for the future treatment of nonmetastatic cancer, according to the researchers. “Our study reveals important differences and specificities in the mechanism of action of high- and low-dose aspirin in metastatic and nonmetastatic cancer cells with different tumor origins and suggests that the ability of aspirin to prevent platelet-induced c-MYC [an oncoprotein] expression might be selective for a nonmetastatic phenotype.

 

N.H.Kh

 

You might also like
Latest news
Syria calls on UN member states to take firm measures and stop Israeli attacks Israeli aggression targets civilian sites south of Damascus Russian Trade Representation in Syria holds a sports marathon to celebrate National Unity Day in Rus... Settlers burn Palestinian lands and homes east of Ramallah Lebanese resistance targets Meron base, settlements and gatherings of the Israeli enemy 43,374 martyrs since the beginning of the Israeli war of extermination on the Gaza Strip Three martyrs in Israeli air raids on southern Lebanon Syrian film (Salma) at Cairo International Film Festival Recreational activities and psychological support in Homs for children arriving from Lebanon Pezeshkian: Iran is facing an economic war to weaken it Palestinian Foreign Ministry: The occupation crimes in the West Bank are part of the war of extermin... The Syria Trust for Development in cooperation with the Finnish Relief Organization: In the Aleppo c... A Palestinian man was shot by the occupation forces near Bethlehem Syrian Postal Corporation issues a commemorative stamp on the occasion of “National Environment Day” The beginning of the winter vegetable season  in Sweida with a plan of 2890 dunums Palestinian Presidency: The world must take concrete steps on the ground against Israel With the participation of 20 Artisans, the Autumn 2024 Exhibition kicks off at Baniyas Culture Cente... Minister of Endowments discusses with Vice President of the Russian Pyatigorsk State University the ... Martyrs and wounded as a result of the occupation's bombing of Al-Nuseirat camp Lebanese National  resistance targets 4 settlements and an Israeli air base